Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,026 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan.
Igarashi A, Hirose E, Kobayashi Y, Yonemoto N, Lee B. Igarashi A, et al. Expert Rev Vaccines. 2022 May;21(5):591-592. doi: 10.1080/14760584.2022.2036129. Epub 2022 Feb 16. Expert Rev Vaccines. 2022. PMID: 35104176 Free article. No abstract available.
Health-related quality of life in health states corresponding to different stages of perianal fistula associated with Crohn's disease: a quantitative evaluation of patients and non-patients in Japan.
Kato M, Yoneyama-Hirozane M, Iwasaki K, Matsubayashi M, Igarashi A. Kato M, et al. Among authors: igarashi a. J Mark Access Health Policy. 2023 Jan 15;11(1):2166374. doi: 10.1080/20016689.2023.2166374. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 36684854 Free PMC article.
Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
Maeda H, Saito N, Igarashi A, Ishida M, Terada M, Ito T, Ikeda H, Kamura H, Motohashi I, Kimura Y, Komino M, Arai H, Kuwamitsu O, Akuzawa N, Sando E, Morikawa T, Imura H, Inoue H, Hayakawa T, Teshigahara O, Ohara Y, Suzuki M, Morimoto K. Maeda H, et al. Among authors: igarashi a. Expert Rev Vaccines. 2023 Jan-Dec;22(1):288-298. doi: 10.1080/14760584.2023.2188950. Expert Rev Vaccines. 2023. PMID: 36883371 Free article.
1,026 results